---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Dosing and administration questions"
description: "Dosing and administration questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Treatment combinations. Questions: How many doses of Prevnar 20 do adults need? Can Prevnar 20 be given with Fluad flu vaccine in adults 65+? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Dosing and administration questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Dosing and administration questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20/dosing-and-administration).

## Dosing

<a id="prevnar20-adult-dose"></a>

### How many doses of Prevnar 20 do adults need?

> “Adults: Administer Prevnar 20 as a single dose in adults 18 years of age and older. (2.6)”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Adults%3A%20Administer%20Prevnar%2020%20as,of%20age%20and%20older.%20%282.6%29)

> “Prevnar 20 is administered as a single dose.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Prevnar%2020%20is%20administered%20as%20a%20single%20dose.)

## Treatment combinations

<a id="prevnar20-flu-vaccine"></a>

### Can Prevnar 20 be given with Fluad flu vaccine in adults 65+?

Applies to: Adults 65 years of age and older given Prevnar 20 with adjuvanted quadrivalent influenza vaccine (Study 7)

> “Study 7 was a double-blind, randomized study conducted in individuals 65 years of age and older who had no history of prior pneumococcal vaccination or who had previously received PPSV23 and/or Prevnar 13 at least 6 months prior to enrollment. Study participants were randomized in a 1:1 ratio to receive Prevnar 20 concomitantly administered with Fluad Quadrivalent followed approximately one month later by placebo (Group 1, N=898) or Fluad Quadrivalent concomitantly administered with placebo followed approximately one month later by Prevnar 20 (Group 2, N=898). Pneumococcal serotype-specific OPA GMTs were evaluated 1 month after Prevnar 20 and influenza vaccine strain hemagglutinin inhibition assay (HAI) GMTs were evaluated 1 month after Fluad Quadrivalent. The noninferiority criteria for the comparisons of OPA GMTs (lower limit of the 2- sided 95% CI of the GMT ratio [Group 1/Group 2] >0.5, 2-fold noninferiority criterion) were met for all 20 pneumococcal serotypes in Prevnar 20. The noninferiority criteria for the comparisons of HAI GMTs (lower limit of the 2- sided 95% CI for the GMT ratio [Group 1/Group 2] >0.67, 1.5-fold noninferiority criterion) were also met for all 4 influenza vaccine strains.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Study%207%20was%20a%20double%2Dblind%2C,all%204%20influenza%20vaccine%20strains.)

> “In Study 7, the rates of local reactions at the Prevnar 20 injection site within 10 days after vaccination were similar between participants who received Prevnar 20 and Fluad Quadrivalent concomitantly (Group 1) or separately (Group 2). The rates of systemic reactions within 7 days following administration of Prevnar 20 were generally numerically higher in Group 1 compared to Group 2; however, overall, fever in both groups was uncommon (<1.5%) and other systemic reactions (fatigue, headache, muscle, or joint pain) were primarily mild to moderate (≤0.9% were severe). The proportions of participants with SAEs occurring within 1 month after vaccination with Prevnar 20 were 1.1% for Group 1 and 1.7% in Group 2. No SAEs occurring within 1 month after vaccination with Prevnar 20 were considered related to vaccination.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=In%20Study%207%2C%20the%20rates,were%20considered%20related%20to%20vaccination.)

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Indication](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety)
- [Specific populations](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations)
- [Guidelines](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines)
